Pulmonx Corp Dossier - Source-backed chat

Pulmonx Corp

LUNGNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.54

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $1.91Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $82M

Enterprise Value $63.7M

Shares Outstanding 42.7M diluted

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Pulmonx Corp is a commercial-stage medical technology company specializing in minimally invasive treatments for severe emphysema. While its flagship Zephyr Endobronchial Valve remains a standard of care with strong clinical backing, the company is currently navigating temporary headwinds. These include a lack of sales in China due to a pending registration renewal and a restructuring of its U.S. commercial sales force. Although Q1 2026 revenue declined 9% year-over-year to $20.6 million, management has taken decisive steps to align costs, reducing operating expenses by over 10% and securing a new $60 million credit facility to extend its cash runway. A 'Hold' recommendation is appropriate as the market awaits tangible signs of revenue acceleration in the second half of 2026 and progress on the pivotal CONVERT II trial for its market-expanding AeriSeal program.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.50

Mean target$3.40

High · most bullish analyst$5.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$2.5015%

The bear case reflects prolonged delays in the China registration renewal and continued friction in the U.S. commercial turnaround, leading to flat or declining procedure volumes. Under this scenario, cash burn would accelerate beyond the projected $23 million for the year, forcing the company to draw down on its credit facility under less favorable terms or seek dilutive equity financing.

Base CaseCentral scenario

$3.4060%

Matches the consensus mean

The base case assumes Pulmonx successfully executes its cost-alignment strategy, keeping full-year 2026 operating expenses within the guided range of $113 million to $115 million. Revenue is expected to recover sequentially, meeting the full-year guidance of $90 million to $92 million, supported by a return to growth in the back half of the year as direct international markets (excluding China) continue to perform well.

Bull CaseUpside scenario

$5.0025%

The bull case is driven by a swift resolution of the China registration renewal, allowing high-margin international sales to resume, combined with rapid productivity gains from the restructured U.S. sales force. Additionally, accelerated enrollment in the CONVERT II trial for AeriSeal could bring the company closer to expanding its global addressable market by 20%, positioning Pulmonx for a strong multi-year growth cycle.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Minimally invasive Zephyr Valve is widely recognized as a standard of care for severe emphysema with strong clinical evidence (e.g., LIBERATE trial).
High gross margin profile (78% in Q1 2026) provides significant operating leverage as sales scale.
Strong balance sheet with $61.6 million in cash and a newly secured $60 million credit facility extending debt maturity to 2031.
AeriSeal program (CONVERT II trial) represents a clear catalyst to expand the global addressable market by 20%.

Key Investment Risks

Concentration of revenue on a single product family (Zephyr Valve) and companion diagnostic tools.
Regulatory and registration delays in key international markets, particularly China.
Execution risk associated with the ongoing restructuring and refocusing of the U.S. sales organization.
Persistent net losses ($13.7 million in Q1 2026) and negative cash flow from operations.

Thesis Invalidation Triggers

Failure to secure the China registration renewal by the end of 2026.
A downward revision of the full-year 2026 revenue guidance below $90 million.
Significant delays in the enrollment timeline for the CONVERT II trial (extending past 2027).
Quarterly cash burn accelerating significantly above the projected run rate.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.